Bifidobacterium infantis is a well-studied probiotic strain naturally found in the human gut, particularly prominent in the intestinal tract during infancy. Research suggests it may play a meaningful role in supporting digestive comfort, with clinical studies — especially those involving the strain B. infantis 35624 — indicating potential benefits for individuals experiencing irritable bowel syndrome symptoms such as bloating, abdominal discomfort, and irregular bowel habits. Studies also point to its ability to support immune function by helping regulate inflammatory responses and promoting a balanced gut environment. Commonly available in capsule form, including the widely recognized Align probiotic brand, B. infantis remains one of the more rigorously investigated probiotic strains, though individual responses can vary and the research continues to evolve.
Compare this supplementResearch suggests that Bifidobacterium infantis 35624 may help reduce certain IBS symptoms — particularly abdominal p...
View studies →Research suggests that Bifidobacterium infantis 35624 may help reduce bloating in people with irritable bowel syndrom...
View studies →Research suggests that Bifidobacterium infantis plays a meaningful role in supporting gut health across multiple biol...
View studies →Research suggests that Bifidobacterium infantis may support immune function through several mechanisms, including mod...
View studies →These are commonly referenced dosage ranges for this supplement. They are not medical recommendations. Always consult a healthcare provider before supplementing.
| Form | Dose range | Frequency | Studied for | Source |
|---|---|---|---|---|
| Capsule | 99,999,999.99 CFU | Daily | Bloating relief | Range observed across multiple RCTs targeting abdominal bloating and discomfort in IBS populations |
| Capsule | 99,999,999.99 CFU | Daily | Gut health and microbiome modulation | Higher doses used in gut microbiota studies; common in probiotic combination formulas for general gut health |
| Capsule | 99,999,999.99 CFU | Daily | IBS relief | Pivotal RCT by Whorwell et al. (2006) in Am J Gastroenterol using 1×10⁹ CFU dose showing significant IBS symptom improvement |
| Powder | 99,999,999.99 CFU | Daily | Immune function | Doses used in clinical studies examining immune modulation and mucosal immunity outcomes |